Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants

NCT05053165 is registered in ClinicalTrials.gov with LISCure Biosciences as lead sponsor.

NCT NCT05053165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants
Lead sponsor
LISCure Biosciences
Phase
Phase 1
Overall status
Completed
Start date
January 4, 2022
Completion date
June 29, 2022
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis, rheumatoid arthritis